Polyfunctional T-cell signatures to predict protection from cytomegalovirus after lung transplantation

American Journal of Respiratory and Critical Care Medicine

Volumn 193, Issue 1, 2016, Pages 78-85

  Snyder, Laurie D ^a   Chan, Cliburn ^a   Kwon, Darongsae ^a   Yi, John S ^a   Martissa, Jessica A ^a   Copeland, C Ashley Finlen ^a   Osborne, Robyn J ^a   Sparks, Sara D ^a   Palmer, Scott M ^a   Weinhold, Kent J ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cytomegalovirus; Immunologic monitoring; Lung transplantation

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CYTOMEGALOVIRUS ANTIGEN PP65; GAMMA INTERFERON; GANCICLOVIR; INTERLEUKIN 2; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; TUMOR NECROSIS FACTOR; VALGANCICLOVIR;

ADULT; AGED; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL STIMULATION; CLINICAL ARTICLE; CLINICAL PROTOCOL; COHORT ANALYSIS; CONTROLLED STUDY; CYTOKINE RESPONSE; CYTOMEGALOVIRUS INFECTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; IMMUNE RESPONSE; INFECTION RISK; LUNG TRANSPLANTATION; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; VALIDATION STUDY; VIREMIA; ADVERSE EFFECTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FLOW CYTOMETRY; GRAFT SURVIVAL; IMMUNOLOGY; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; RISK FACTOR;

AGED; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; FLOW CYTOMETRY; GRAFT SURVIVAL; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-2; LUNG TRANSPLANTATION; LYSOSOMAL-ASSOCIATED MEMBRANE PROTEIN 1; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA; VIREMIA;

EID: 84988859916     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201504-0733OC     Document Type: Article

References (32)

1. Kotton CN, Kumar D, Caliendo AM, Asberg A, Chou S, Danziger-Isakov L, Humar A; Transplantation Society International CMV Consensus Group. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation 2013;96:333-360.
2. Roman A, Manito N, Campistol JM, Cuervas-Mons V, Almenar L, Arias M, Casafont F, del Castillo D, Crespo-Leiro MG, Delgado JF, et al.; ATOS Working Group. The impact of the prevention strategies on the indirect effects of CMV infection in solid organ transplant recipients. Transplant Rev (Orlando) 2014;28:84-91.
3. Snyder LD, Finlen-Copeland CA, Turbyfill WJ, Howell D, Willner DA, Palmer SM. Cytomegalovirus pneumonitis is a risk for bronchiolitis obliterans syndrome in lung transplantation. Am J Respir Crit Care Med 2010;181:1391-1396.
4. Westall GP, Michaelides A, Williams TJ, Snell GI, Kotsimbos TC. Bronchiolitis obliterans syndrome and early human cytomegalovirus DNAaemia dynamics after lung transplantation. Transplantation 2003;75:2064-2068.
5. Paraskeva M, Bailey M, Levvey BJ, Griffiths AP, Kotsimbos TC, Williams TP, Snell G, Westall G. Cytomegalovirus replication within the lung allograft is associated with bronchiolitis obliterans syndrome. Am J Transplant 2011;11:2190-2196.
6. Zuk DM, Humar A, Weinkauf JG, Lien DC, Nador RG, Kumar D. An international survey of cytomegalovirus management practices in lung transplantation. Transplantation 2010;90:672-676.
7. Manuel O, Husain S, Kumar D, Zayas C, Mawhorter S, Levi ME, Kalpoe J, Lisboa L, Ely L, Kaul DR, et al. Assessment of cytomegalovirusspecific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study. Clin Infect Dis 2013;56:817-824.
8. Kumar D, Chernenko S, Moussa G, Cobos I, Manuel O, Preiksaitis J, Venkataraman S, Humar A. Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients. Am J Transplant 2009;9:1214-1222.
9. Snyder LD, Medinas R, Chan C, Sparks S, Davis WA, Palmer SM, Weinhold KJ. Polyfunctional cytomegalovirus-specific immunity in lung transplant recipients receiving valganciclovir prophylaxis. Am J Transplant 2011;11:553-560.
10. Betts MR, Nason MC, West SM, De Rosa SC, Migueles SA, Abraham J, Lederman MM, Benito JM, Goepfert PA, Connors M, et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD81 T cells. Blood 2006;107:4781-4789.
11. de Silva TI, Peng Y, Leligdowicz A, Zaidi I, Li L, Griffin H, Blais ME, Vincent T, Saraiva M, Yindom LM, et al. Correlates of T-cell-mediated viral control and phenotype of CD8(1) T cells in HIV-2, a naturally contained human retroviral infection. Blood 2013;121:4330-4339.
12. Darrah PA, Patel DT, De Luca PM, Lindsay RW, Davey DF, Flynn BJ, Hoff ST, Andersen P, Reed SG, Morris SL, et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 2007;13:843-850.
13. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996;15:361-387.
14. Shuster JJ. Median follow-up in clinical trials. J Clin Oncol 1991;9: 191-192.
15. Kern F, Khatamzas E, Surel I, Frömmel C, Reinke P, Waldrop SL, Picker LJ, Volk HD. Distribution of human CMV-specific memory T cells among the CD8pos. subsets defined by CD57, CD27, and CD45 isoforms. Eur J Immunol 1999;29:2908-2915.
16. Nickel P, Bold G, Presber F, Biti D, Babel N, Kreutzer S, Pratschke J, Schönemann C, Kern F, Volk HD, et al. High levels of CMV-IE-1-specific memory T cells are associated with less alloimmunity and improved renal allograft function. Transpl Immunol 2009;20:238-242.
17. Bunde T, Kirchner A, Hoffmeister B, Habedank D, Hetzer R, Cherepnev G, Proesch S, Reinke P, Volk HD, Lehmkuhl H, et al. Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells. J Exp Med 2005;201:1031-1036.
18. Egli A, Humar A, Kumar D. State-of-the-art monitoring of cytomegalovirus-specific cell-mediated immunity after organ transplant: a primer for the clinician. Clin Infect Dis 2012;55: 1678-1689.
19. Westall GP, Mifsud NA, Kotsimbos T. Linking CMV serostatus to episodes of CMV reactivation following lung transplantation by measuring CMV-specific CD81 T-cell immunity. Am J Transplant 2008;8:1749-1754.
20. Weseslindtner L, Kerschner H, Steinacher D, Nachbagauer R, Kundi M, Jaksch P, Simon B, Hatos-Agyi L, Scheed A, Klepetko W, et al. Prospective analysis of human cytomegalovirus DNAemia and specific CD81 T cell responses in lung transplant recipients. Am J Transplant 2012;12:2172-2180.
21. van Lier RA, ten Berge IJ, Gamadia LE. Human CD8(1) T-cell differentiation in response to viruses. Nat Rev Immunol 2003;3: 931-939.
22. Sester M, Sester U, Gärtner BC, Girndt M, Meyerhans A, Köhler H. Dominance of virus-specific CD8 T cells in human primary cytomegalovirus infection. J Am Soc Nephrol 2002;13:2577-2584.
23. Pipeling MR, West EE, Osborne CM, Whitlock AB, Dropulic LK, Willett MH, Forman M, Valsamakis A, Orens JB, Moller DR, et al. Differential CMV-specific CD81 effector T cell responses in the lung allograft predominate over the blood during human primary infection. J Immunol 2008;181:546-556.
24. Tu W, Potena L, Stepick-Biek P, Liu L, Dionis KY, Luikart H, Fearon WF, Holmes TH, Chin C, Cooke JP, et al. T-cell immunity to subclinical cytomegalovirus infection reduces cardiac allograft disease. Circulation 2006;114:1608-1615.
25. Gerna G, Lilleri D, Chiesa A, Zelini P, Furione M, Comolli G, Pellegrini C, Sarchi E, Migotto C, Bonora MR, et al. Virologic and immunologic monitoring of cytomegalovirus to guide preemptive therapy in solid-organ transplantation. Am J Transplant 2011;11: 2463-2471.
26. Chiereghin A, Gabrielli L, Zanfi C, Petrisli E, Lauro A, Piccirilli G, Baccolini F, Dazzi A, Cescon M, Morelli MC, et al. Monitoring cytomegalovirus T-cell immunity in small bowel/multivisceral transplant recipients. Transplant Proc 2010;42:69-73.
27. Sester M, Sester U, Gärtner B, Heine G, Girndt M, Mueller-Lantzsch N, Meyerhans A, Köhler H. Levels of virus-specific CD4 T cells correlate with cytomegalovirus control and predict virus-induced disease after renal transplantation. Transplantation 2001;71:1287-1294.
28. Sester U, Gärtner BC, Wilkens H, Schwaab B, Wössner R, Kindermann I, Girndt M, Meyerhans A, Mueller-Lantzsch N, Schäfers HJ, et al. Differences in CMV-specific T-cell levels and long-term susceptibility to CMV infection after kidney, heart and lung transplantation. Am J Transplant 2005;5:1483-1489.
29. Ciuffreda D, Comte D, Cavassini M, Giostra E, Bühler L, Perruchoud M, Heim MH, Battegay M, GennéD, Mulhaupt B, et al. Polyfunctional HCV-specific T-cell responses are associated with effective control of HCV replication. Eur J Immunol 2008;38:2665-2677.
30. Makedonas G, Betts MR. Polyfunctional analysis of human t cell responses: importance in vaccine immunogenicity and natural infection. Springer Semin Immunopathol 2006;28:209-219.
31. Precopio ML, Betts MR, Parrino J, Price DA, Gostick E, Ambrozak DR, Asher TE, Douek DC, Harari A, Pantaleo G, et al. Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(1) T cell responses. J Exp Med 2007;204:1405-1416.
32. Kannanganat S, Ibegbu C, Chennareddi L, Robinson HL, Amara RR. Multiple-cytokine-producing antiviral CD4 T cells are functionally superior to single-cytokine-producing cells. J Virol 2007;81: 8468-8476.